Biricodar

Biricodar
Clinical data
Pregnancy; category	AU: A / B1 / B2 / B3 / C / D / X ; US: A / B / C / D / X ; ;
ATC code	none;
Legal status
Legal status	AU: Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 ; CA: Schedule I, II, III, IV, V, VI, VII, VIII ; UK: GSL / P / POM / CD / Class A, B, C ; US: OTC / Rx-only / Schedule I, II, III, IV, V ;
Identifiers
	IUPAC name 1,7-di(pyridin-3-yl)heptan-4-yl (2S)-1-[oxo(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate;
CAS Number	174254-13-8 ;
PubChem CID	3037617;
ChemSpider	2301309 ;
UNII	9WQP0L619L;
ChEMBL	ChEMBL350775 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C34H41N3O7
Molar mass	603.716 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(C(=O)c1cc(OC)c(OC)c(OC)c1)N4[C@H](C(=O)OC(CCCc2cccnc2)CCCc3cccnc3)CCCC4;
	InChI InChI=1S/C34H41N3O7/c1-41-29-20-26(21-30(42-2)32(29)43-3)31(38)33(39)37-19-5-4-16-28(37)34(40)44-27(14-6-10-24-12-8-17-35-22-24)15-7-11-25-13-9-18-36-23-25/h8-9,12-13,17-18,20-23,27-28H,4-7,10-11,14-16,19H2,1-3H3/t28-/m0/s1 ; Key:CGVWPQOFHSAKRR-NDEPHWFRSA-N ;
(verify)

Biricodar or incel (INN, codename VX-710) was a pharmaceutical drug under development by Vertex Pharmaceuticals to help treat ovarian cancer patients.^[1] The drug never reached the market.

References

↑ Dey S (May 2002). "Biricodar. Vertex Pharmaceuticals". Current Opinion in Investigational Drugs. London, England. 3 (5): 818–23. doi:10.2174/138945006777709593. PMID 12090559.

Nobili S, Landini I, Giglioni B, Mini E (July 2006). "Pharmacological strategies for overcoming multidrug resistance". Current Drug Targets. 7 (7): 861–79. doi:10.2174/138945006777709593. PMID 16842217.
Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD (March 2002). "Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel". Clinical Cancer Research. 8 (3): 670–8. PMID 11895894.

This antineoplastic or immunomodulatory drug article is a stub. You can help EverybodyWiki by expanding it.

This article "Biricodar" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Biricodar. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.

Clinical data

Pregnancy category	AU: A / B1 / B2 / B3 / C / D / X US: A / B / C / D / X
ATC code	none
Legal status
Legal status	AU: Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 CA: Schedule I, II, III, IV, V, VI, VII, VIII UK: GSL / P / POM / CD / Class A, B, C US: OTC / Rx-only / Schedule I, II, III, IV, V
Identifiers
IUPAC name 1,7-di(pyridin-3-yl)heptan-4-yl (2S)-1-[oxo(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carboxylate
CAS Number	174254-13-8^Y
PubChem CID	3037617
ChemSpider	2301309^Y
UNII	9WQP0L619L
ChEMBL	ChEMBL350775^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C₃₄H₄₁N₃O₇
Molar mass	603.716 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=C(C(=O)c1cc(OC)c(OC)c(OC)c1)N4[C@H](C(=O)OC(CCCc2cccnc2)CCCc3cccnc3)CCCC4
InChI InChI=1S/C34H41N3O7/c1-41-29-20-26(21-30(42-2)32(29)43-3)31(38)33(39)37-19-5-4-16-28(37)34(40)44-27(14-6-10-24-12-8-17-35-22-24)15-7-11-25-13-9-18-36-23-25/h8-9,12-13,17-18,20-23,27-28H,4-7,10-11,14-16,19H2,1-3H3/t28-/m0/s1^Y Key:CGVWPQOFHSAKRR-NDEPHWFRSA-N^Y
(verify)